AxoGen, Inc. (NASDAQ: AXGN) Stock Competitors & Peer Comparison
See AXGN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for AXGN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AXGN | $34.62 | -2.83% | 2B | 91.13 | $0.38 | N/A |
| ABT | $103.76 | -0.88% | 181.5B | 20.13 | $5.21 | +2.40% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $92.75 | -2.83% | 121.2B | 17.14 | $5.53 | +3.02% |
| SYK | $296.23 | +1.02% | 113B | 22.01 | $13.39 | +1.20% |
| BSX | $44.35 | +0.46% | 64.3B | 14.32 | $3.10 | N/A |
| EW | $87.23 | -0.99% | 49.9B | 32.07 | $2.70 | N/A |
| DXCM | $85.65 | -2.35% | 32.5B | 33.74 | $2.55 | N/A |
| GEHC | $69.53 | -1.16% | 31.4B | 15.26 | $4.56 | +0.20% |
| PHG | $25.55 | +0.22% | 24.9B | 14.72 | $1.75 | +3.84% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
AXGN vs ABT Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, ABT has a market cap of 181.5B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while ABT trades at $103.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas ABT's P/E ratio is 20.13. In terms of profitability, AXGN's ROE is -0.18%, compared to ABT's ROE of +0.11%. Regarding short-term risk, AXGN is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
AXGN vs BSX-PA Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, AXGN's ROE is -0.18%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, AXGN is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check BSX-PA's competition here
Medtronic Plc (NYSE: MDT)
AXGN vs MDT Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, MDT has a market cap of 121.2B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while MDT trades at $92.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas MDT's P/E ratio is 17.14. In terms of profitability, AXGN's ROE is -0.18%, compared to MDT's ROE of +0.11%. Regarding short-term risk, AXGN is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
AXGN vs SYK Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, SYK has a market cap of 113B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while SYK trades at $296.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas SYK's P/E ratio is 22.01. In terms of profitability, AXGN's ROE is -0.18%, compared to SYK's ROE of +0.16%. Regarding short-term risk, AXGN is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
AXGN vs BSX Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, BSX has a market cap of 64.3B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while BSX trades at $44.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas BSX's P/E ratio is 14.32. In terms of profitability, AXGN's ROE is -0.18%, compared to BSX's ROE of +0.15%. Regarding short-term risk, AXGN is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
AXGN vs EW Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, EW has a market cap of 49.9B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while EW trades at $87.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas EW's P/E ratio is 32.07. In terms of profitability, AXGN's ROE is -0.18%, compared to EW's ROE of +0.10%. Regarding short-term risk, AXGN is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
AXGN vs DXCM Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, DXCM has a market cap of 32.5B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while DXCM trades at $85.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas DXCM's P/E ratio is 33.74. In terms of profitability, AXGN's ROE is -0.18%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, AXGN is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
AXGN vs GEHC Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, GEHC has a market cap of 31.4B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while GEHC trades at $69.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas GEHC's P/E ratio is 15.26. In terms of profitability, AXGN's ROE is -0.18%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, AXGN is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
AXGN vs PHG Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, PHG has a market cap of 24.9B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while PHG trades at $25.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas PHG's P/E ratio is 14.72. In terms of profitability, AXGN's ROE is -0.18%, compared to PHG's ROE of +0.10%. Regarding short-term risk, AXGN is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
AXGN vs ZBH Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, ZBH has a market cap of 18.1B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while ZBH trades at $94.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas ZBH's P/E ratio is 11.20. In terms of profitability, AXGN's ROE is -0.18%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, AXGN is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
AXGN vs ABMD Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas ABMD's P/E ratio is 65.36. In terms of profitability, AXGN's ROE is -0.18%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, AXGN is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
AXGN vs PEN Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while PEN trades at $321.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas PEN's P/E ratio is 83.79. In terms of profitability, AXGN's ROE is -0.18%, compared to PEN's ROE of +0.11%. Regarding short-term risk, AXGN is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
AXGN vs SWAV Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas SWAV's P/E ratio is 78.76. In terms of profitability, AXGN's ROE is -0.18%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, AXGN is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
AXGN vs SNN Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, SNN has a market cap of 12.2B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while SNN trades at $28.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas SNN's P/E ratio is 19.62. In terms of profitability, AXGN's ROE is -0.18%, compared to SNN's ROE of +0.12%. Regarding short-term risk, AXGN is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
AXGN vs ALGN Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, ALGN has a market cap of 10.5B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while ALGN trades at $147.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas ALGN's P/E ratio is 13.43. In terms of profitability, AXGN's ROE is -0.18%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, AXGN is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
AXGN vs GMED Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, GMED has a market cap of 10.3B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while GMED trades at $76.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas GMED's P/E ratio is 17.27. In terms of profitability, AXGN's ROE is -0.18%, compared to GMED's ROE of +0.12%. Regarding short-term risk, AXGN is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check GMED's competition here
Insulet Corp. (NASDAQ: PODD)
AXGN vs PODD Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, PODD has a market cap of 9.8B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while PODD trades at $140.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas PODD's P/E ratio is 24.04. In terms of profitability, AXGN's ROE is -0.18%, compared to PODD's ROE of +0.27%. Regarding short-term risk, AXGN is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check PODD's competition here
Glaukos Corporation (NYSE: GKOS)
AXGN vs GKOS Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, GKOS has a market cap of 9.7B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while GKOS trades at $167.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas GKOS's P/E ratio is -191.66. In terms of profitability, AXGN's ROE is -0.18%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, AXGN is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check GKOS's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
AXGN vs BIO-B Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, BIO-B has a market cap of 9.6B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while BIO-B trades at $355.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas BIO-B's P/E ratio is -62.58. In terms of profitability, AXGN's ROE is -0.18%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, AXGN is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
AXGN vs BIO Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, BIO has a market cap of 9.5B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while BIO trades at $353.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas BIO's P/E ratio is 38.12. In terms of profitability, AXGN's ROE is -0.18%, compared to BIO's ROE of +0.03%. Regarding short-term risk, AXGN is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check BIO's competition here
Masimo Corporation (NASDAQ: MASI)
AXGN vs MASI Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas MASI's P/E ratio is 44.43. In terms of profitability, AXGN's ROE is -0.18%, compared to MASI's ROE of +0.09%. Regarding short-term risk, AXGN is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
AXGN vs BRKR Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, BRKR has a market cap of 8.3B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while BRKR trades at $54.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas BRKR's P/E ratio is 27.54. In terms of profitability, AXGN's ROE is -0.18%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, AXGN is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
AXGN vs BRKRP Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, BRKRP has a market cap of 8.3B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while BRKRP trades at $408.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas BRKRP's P/E ratio is 220.46. In terms of profitability, AXGN's ROE is -0.18%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, AXGN is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check BRKRP's competition here
Haemonetics Corporation (NYSE: HAE)
AXGN vs HAE Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, HAE has a market cap of 5.4B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while HAE trades at $118.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas HAE's P/E ratio is 23.62. In terms of profitability, AXGN's ROE is -0.18%, compared to HAE's ROE of +0.11%. Regarding short-term risk, AXGN is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
AXGN vs NARI Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas NARI's P/E ratio is -59.24. In terms of profitability, AXGN's ROE is -0.18%, compared to NARI's ROE of -0.00%. Regarding short-term risk, AXGN is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
AXGN vs ITGR Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while ITGR trades at $126.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas ITGR's P/E ratio is 19.96. In terms of profitability, AXGN's ROE is -0.18%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, AXGN is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
AXGN vs LIVN Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, LIVN has a market cap of 4.3B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while LIVN trades at $78.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas LIVN's P/E ratio is 18.43. In terms of profitability, AXGN's ROE is -0.18%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, AXGN is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
AXGN vs IRTC Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, IRTC has a market cap of 3.6B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while IRTC trades at $110.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas IRTC's P/E ratio is -252.70. In terms of profitability, AXGN's ROE is -0.18%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, AXGN is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check IRTC's competition here
Neogen Corporation (NASDAQ: NEOG)
AXGN vs NEOG Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while NEOG trades at $11.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas NEOG's P/E ratio is 42.18. In terms of profitability, AXGN's ROE is -0.18%, compared to NEOG's ROE of -0.03%. Regarding short-term risk, AXGN is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check NEOG's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
AXGN vs TMDX Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while TMDX trades at $72.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas TMDX's P/E ratio is 35.93. In terms of profitability, AXGN's ROE is -0.18%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, AXGN is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check TMDX's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
AXGN vs UFPT Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while UFPT trades at $294.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas UFPT's P/E ratio is 29.79. In terms of profitability, AXGN's ROE is -0.18%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, AXGN is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check UFPT's competition here
NuVasive, Inc. (NASDAQ: NUVA)
AXGN vs NUVA Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas NUVA's P/E ratio is 75.00. In terms of profitability, AXGN's ROE is -0.18%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, AXGN is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check NUVA's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
AXGN vs INSP Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, INSP has a market cap of 2B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while INSP trades at $69.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas INSP's P/E ratio is 30.30. In terms of profitability, AXGN's ROE is -0.18%, compared to INSP's ROE of +0.18%. Regarding short-term risk, AXGN is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check INSP's competition here
Butterfly Network, Inc. (NYSE: BFLY)
AXGN vs BFLY Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, BFLY has a market cap of 1.9B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while BFLY trades at $7.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas BFLY's P/E ratio is -30.21. In terms of profitability, AXGN's ROE is -0.18%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, AXGN is more volatile compared to BFLY. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check BFLY's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
AXGN vs ESTA Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, ESTA has a market cap of 1.8B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while ESTA trades at $59.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas ESTA's P/E ratio is -46.96. In terms of profitability, AXGN's ROE is -0.18%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, AXGN is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
AXGN vs NVCR Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, NVCR has a market cap of 1.6B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while NVCR trades at $14.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas NVCR's P/E ratio is -10.82. In terms of profitability, AXGN's ROE is -0.18%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, AXGN is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check NVCR's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
AXGN vs ATEC Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while ATEC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas ATEC's P/E ratio is -174.33. In terms of profitability, AXGN's ROE is -0.18%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, AXGN is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
AXGN vs CNMD Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while CNMD trades at $46.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas CNMD's P/E ratio is 10.27. In terms of profitability, AXGN's ROE is -0.18%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, AXGN is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check CNMD's competition here
Picard Medical, Inc. (AMEX: PMI)
AXGN vs PMI Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, PMI has a market cap of 1.3B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while PMI trades at $14.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas PMI's P/E ratio is -10.70. In terms of profitability, AXGN's ROE is -0.18%, compared to PMI's ROE of -9.31%. Regarding short-term risk, AXGN is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check PMI's competition here
Heska Corporation (NASDAQ: HSKA)
AXGN vs HSKA Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas HSKA's P/E ratio is -62.49. In terms of profitability, AXGN's ROE is -0.18%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, AXGN is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check HSKA's competition here
Avanos Medical, Inc. (NYSE: AVNS)
AXGN vs AVNS Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas AVNS's P/E ratio is 27.77. In terms of profitability, AXGN's ROE is -0.18%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, AXGN is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check AVNS's competition here
Enovis Corporation (NYSE: ENOV)
AXGN vs ENOV Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while ENOV trades at $19.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas ENOV's P/E ratio is 5.62. In terms of profitability, AXGN's ROE is -0.18%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, AXGN is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check ENOV's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
AXGN vs TNDM Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while TNDM trades at $16.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas TNDM's P/E ratio is -17.46. In terms of profitability, AXGN's ROE is -0.18%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, AXGN is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check TNDM's competition here
IRadimed Corporation (NASDAQ: IRMD)
AXGN vs IRMD Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while IRMD trades at $88.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas IRMD's P/E ratio is 44.36. In terms of profitability, AXGN's ROE is -0.18%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, AXGN is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check IRMD's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
AXGN vs SILK Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas SILK's P/E ratio is -18.96. In terms of profitability, AXGN's ROE is -0.18%, compared to SILK's ROE of -0.35%. Regarding short-term risk, AXGN is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
AXGN vs FNA Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas FNA's P/E ratio is -19.83. In terms of profitability, AXGN's ROE is -0.18%, compared to FNA's ROE of -0.35%. Regarding short-term risk, AXGN is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check FNA's competition here
Artivion, Inc. (NYSE: AORT)
AXGN vs AORT Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while AORT trades at $21.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas AORT's P/E ratio is 36.28. In terms of profitability, AXGN's ROE is -0.18%, compared to AORT's ROE of -0.01%. Regarding short-term risk, AXGN is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check AORT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
AXGN vs LMRI Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, LMRI has a market cap of 1B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while LMRI trades at $10.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas LMRI's P/E ratio is -20.99. In terms of profitability, AXGN's ROE is -0.18%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, AXGN is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check LMRI's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
AXGN vs IART Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, IART has a market cap of 1B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while IART trades at $13.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas IART's P/E ratio is 5.60. In terms of profitability, AXGN's ROE is -0.18%, compared to IART's ROE of -0.01%. Regarding short-term risk, AXGN is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check IART's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
AXGN vs PRCT Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, PRCT has a market cap of 1B. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while PRCT trades at $17.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas PRCT's P/E ratio is -9.06. In terms of profitability, AXGN's ROE is -0.18%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, AXGN is more volatile compared to PRCT. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check PRCT's competition here
CeriBell, Inc. (NASDAQ: CBLL)
AXGN vs CBLL Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, CBLL has a market cap of 960.8M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while CBLL trades at $25.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas CBLL's P/E ratio is -14.22. In terms of profitability, AXGN's ROE is -0.18%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, AXGN is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check CBLL's competition here
Bioventus Inc. (NASDAQ: BVS)
AXGN vs BVS Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, BVS has a market cap of 909.5M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while BVS trades at $13.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas BVS's P/E ratio is 17.52. In terms of profitability, AXGN's ROE is -0.18%, compared to BVS's ROE of +0.28%. Regarding short-term risk, AXGN is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check BVS's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
AXGN vs SIBN Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, SIBN has a market cap of 882M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while SIBN trades at $19.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas SIBN's P/E ratio is -57.88. In terms of profitability, AXGN's ROE is -0.18%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, AXGN is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check SIBN's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
AXGN vs CSII Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas CSII's P/E ratio is -20.83. In terms of profitability, AXGN's ROE is -0.18%, compared to CSII's ROE of -0.14%. Regarding short-term risk, AXGN is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check CSII's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
AXGN vs AHCO Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, AHCO has a market cap of 820.8M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while AHCO trades at $5.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas AHCO's P/E ratio is 12.29. In terms of profitability, AXGN's ROE is -0.18%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, AXGN is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check AHCO's competition here
InMode Ltd. (NASDAQ: INMD)
AXGN vs INMD Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, INMD has a market cap of 814.8M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while INMD trades at $14.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas INMD's P/E ratio is 9.83. In terms of profitability, AXGN's ROE is -0.18%, compared to INMD's ROE of +0.12%. Regarding short-term risk, AXGN is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check INMD's competition here
Varex Imaging Corporation (NASDAQ: VREX)
AXGN vs VREX Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, VREX has a market cap of 781.8M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while VREX trades at $18.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas VREX's P/E ratio is 19.38. In terms of profitability, AXGN's ROE is -0.18%, compared to VREX's ROE of +0.05%. Regarding short-term risk, AXGN is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check VREX's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
AXGN vs BBNX Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, BBNX has a market cap of 737.4M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while BBNX trades at $17.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas BBNX's P/E ratio is -9.93. In terms of profitability, AXGN's ROE is -0.18%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, AXGN is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check BBNX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
AXGN vs CTKB Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, CTKB has a market cap of 682.4M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while CTKB trades at $5.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas CTKB's P/E ratio is -27.81. In terms of profitability, AXGN's ROE is -0.18%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, AXGN is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check CTKB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
AXGN vs SRDX Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas SRDX's P/E ratio is -34.66. In terms of profitability, AXGN's ROE is -0.18%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, AXGN is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check SRDX's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
AXGN vs AVR Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, AVR has a market cap of 589.6M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while AVR trades at $6.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas AVR's P/E ratio is -3.12. In terms of profitability, AXGN's ROE is -0.18%, compared to AVR's ROE of -0.78%. Regarding short-term risk, AXGN is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check AVR's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
AXGN vs APEN Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas APEN's P/E ratio is -9.43. In terms of profitability, AXGN's ROE is -0.18%, compared to APEN's ROE of -0.85%. Regarding short-term risk, AXGN is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check APEN's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
AXGN vs KIDS Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, KIDS has a market cap of 571.8M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while KIDS trades at $22.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas KIDS's P/E ratio is -18.56. In terms of profitability, AXGN's ROE is -0.18%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, AXGN is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check KIDS's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
AXGN vs PACB Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, PACB has a market cap of 537.7M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while PACB trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas PACB's P/E ratio is -4.22. In terms of profitability, AXGN's ROE is -0.18%, compared to PACB's ROE of -49.62%. Regarding short-term risk, AXGN is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check PACB's competition here
ZimVie Inc. (NASDAQ: ZIMV)
AXGN vs ZIMV Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, AXGN's ROE is -0.18%, compared to ZIMV's ROE of -0.07%. Regarding short-term risk, AXGN is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check ZIMV's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
AXGN vs TCMD Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, TCMD has a market cap of 510.1M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while TCMD trades at $22.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas TCMD's P/E ratio is 20.85. In terms of profitability, AXGN's ROE is -0.18%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, AXGN is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check TCMD's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
AXGN vs SSII Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, SSII has a market cap of 507.2M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while SSII trades at $2.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas SSII's P/E ratio is -42.17. In terms of profitability, AXGN's ROE is -0.18%, compared to SSII's ROE of -0.27%. Regarding short-term risk, AXGN is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check SSII's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
AXGN vs DCTH Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, DCTH has a market cap of 488.4M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while DCTH trades at $14.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas DCTH's P/E ratio is 1407.50. In terms of profitability, AXGN's ROE is -0.18%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, AXGN is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check DCTH's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
AXGN vs SGHT Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, SGHT has a market cap of 456.1M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while SGHT trades at $8.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas SGHT's P/E ratio is -14.79. In terms of profitability, AXGN's ROE is -0.18%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, AXGN is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check SGHT's competition here
Cerus Corporation (NASDAQ: CERS)
AXGN vs CERS Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, CERS has a market cap of 437.3M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while CERS trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas CERS's P/E ratio is -72.09. In terms of profitability, AXGN's ROE is -0.18%, compared to CERS's ROE of -0.10%. Regarding short-term risk, AXGN is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
AXGN vs NPCE Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, NPCE has a market cap of 420.1M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while NPCE trades at $12.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas NPCE's P/E ratio is -21.47. In terms of profitability, AXGN's ROE is -0.18%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, AXGN is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check NPCE's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
AXGN vs SENS Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, SENS has a market cap of 410.8M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while SENS trades at $7.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas SENS's P/E ratio is -3.48. In terms of profitability, AXGN's ROE is -0.18%, compared to SENS's ROE of -1.66%. Regarding short-term risk, AXGN is more volatile compared to SENS. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
AXGN vs OFIX Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, OFIX has a market cap of 379.2M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while OFIX trades at $9.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas OFIX's P/E ratio is -6.11. In terms of profitability, AXGN's ROE is -0.18%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, AXGN is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check OFIX's competition here
CapsoVision, Inc. (NASDAQ: CV)
AXGN vs CV Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, CV has a market cap of 347.5M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while CV trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas CV's P/E ratio is -10.37. In terms of profitability, AXGN's ROE is -0.18%, compared to CV's ROE of -1.78%. Regarding short-term risk, AXGN is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check CV's competition here
Avita Medical Inc. (NASDAQ: RCEL)
AXGN vs RCEL Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, RCEL has a market cap of 324M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while RCEL trades at $13.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas RCEL's P/E ratio is -9.06. In terms of profitability, AXGN's ROE is -0.18%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, AXGN is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check RCEL's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
AXGN vs SMLR Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas SMLR's P/E ratio is 3.92. In terms of profitability, AXGN's ROE is -0.18%, compared to SMLR's ROE of +0.20%. Regarding short-term risk, AXGN is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check SMLR's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
AXGN vs CLPT Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, CLPT has a market cap of 276.7M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while CLPT trades at $9.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas CLPT's P/E ratio is -7.69. In terms of profitability, AXGN's ROE is -0.18%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, AXGN is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check CLPT's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
AXGN vs INFU Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, INFU has a market cap of 266.9M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while INFU trades at $13.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas INFU's P/E ratio is 32.68. In terms of profitability, AXGN's ROE is -0.18%, compared to INFU's ROE of +0.15%. Regarding short-term risk, AXGN is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check INFU's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
AXGN vs TMCI Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, TMCI has a market cap of 251.7M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while TMCI trades at $3.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas TMCI's P/E ratio is -4.12. In terms of profitability, AXGN's ROE is -0.18%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, AXGN is more volatile compared to TMCI. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check TMCI's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
AXGN vs CATX Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, CATX has a market cap of 247.7M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while CATX trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas CATX's P/E ratio is -1.63. In terms of profitability, AXGN's ROE is -0.18%, compared to CATX's ROE of -0.42%. Regarding short-term risk, AXGN is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check CATX's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
AXGN vs MGRM Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas MGRM's P/E ratio is -12.00. In terms of profitability, AXGN's ROE is -0.18%, compared to MGRM's ROE of -1.17%. Regarding short-term risk, AXGN is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
AXGN vs ELMD Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, ELMD has a market cap of 228.1M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while ELMD trades at $27.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas ELMD's P/E ratio is 21.02. In terms of profitability, AXGN's ROE is -0.18%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, AXGN is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
AXGN vs NVRO Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas NVRO's P/E ratio is -1.91. In terms of profitability, AXGN's ROE is -0.18%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, AXGN is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check NVRO's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
AXGN vs TLSI Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, TLSI has a market cap of 223.5M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while TLSI trades at $3.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas TLSI's P/E ratio is -2.16. In terms of profitability, AXGN's ROE is -0.18%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, AXGN is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check TLSI's competition here
Quantum-Si incorporated (NASDAQ: QSI)
AXGN vs QSI Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, QSI has a market cap of 222.8M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while QSI trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas QSI's P/E ratio is -2.43. In terms of profitability, AXGN's ROE is -0.18%, compared to QSI's ROE of -0.47%. Regarding short-term risk, AXGN is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check QSI's competition here
Profound Medical Corp. (NASDAQ: PROF)
AXGN vs PROF Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, PROF has a market cap of 219.6M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while PROF trades at $5.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas PROF's P/E ratio is -6.13. In terms of profitability, AXGN's ROE is -0.18%, compared to PROF's ROE of -0.56%. Regarding short-term risk, AXGN is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check PROF's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
AXGN vs BSGM Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas BSGM's P/E ratio is -5.81. In terms of profitability, AXGN's ROE is -0.18%, compared to BSGM's ROE of +6.96%. Regarding short-term risk, AXGN is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check BSGM's competition here
RxSight, Inc. (NASDAQ: RXST)
AXGN vs RXST Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, RXST has a market cap of 187.6M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while RXST trades at $4.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas RXST's P/E ratio is -3.99. In terms of profitability, AXGN's ROE is -0.18%, compared to RXST's ROE of -0.17%. Regarding short-term risk, AXGN is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check RXST's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
AXGN vs MDGS Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas MDGS's P/E ratio is -0.27. In terms of profitability, AXGN's ROE is -0.18%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, AXGN is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check MDGS's competition here
Inogen, Inc. (NASDAQ: INGN)
AXGN vs INGN Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, INGN has a market cap of 165.9M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while INGN trades at $6.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas INGN's P/E ratio is -6.87. In terms of profitability, AXGN's ROE is -0.18%, compared to INGN's ROE of -0.13%. Regarding short-term risk, AXGN is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check INGN's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
AXGN vs QIPT Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas QIPT's P/E ratio is -15.87. In terms of profitability, AXGN's ROE is -0.18%, compared to QIPT's ROE of -0.08%. Regarding short-term risk, AXGN is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
AXGN vs FOCL Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, FOCL has a market cap of 154.8M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while FOCL trades at $4.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas FOCL's P/E ratio is -3.99. In terms of profitability, AXGN's ROE is -0.18%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, AXGN is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check FOCL's competition here
Neuronetics, Inc. (NASDAQ: STIM)
AXGN vs STIM Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, STIM has a market cap of 143.6M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while STIM trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas STIM's P/E ratio is -4.28. In terms of profitability, AXGN's ROE is -0.18%, compared to STIM's ROE of -1.51%. Regarding short-term risk, AXGN is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check STIM's competition here
Quanterix Corporation (NASDAQ: QTRX)
AXGN vs QTRX Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, QTRX has a market cap of 135.7M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while QTRX trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas QTRX's P/E ratio is -1.13. In terms of profitability, AXGN's ROE is -0.18%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, AXGN is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check QTRX's competition here
Owlet, Inc. (NYSE: OWLT)
AXGN vs OWLT Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, OWLT has a market cap of 120.1M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while OWLT trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas OWLT's P/E ratio is -29.36. In terms of profitability, AXGN's ROE is -0.18%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, AXGN is more volatile compared to OWLT. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check OWLT's competition here
iCAD, Inc. (NASDAQ: ICAD)
AXGN vs ICAD Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas ICAD's P/E ratio is -20.37. In terms of profitability, AXGN's ROE is -0.18%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, AXGN is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
AXGN vs HJLI Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas HJLI's P/E ratio is N/A. In terms of profitability, AXGN's ROE is -0.18%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, AXGN is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
AXGN vs ASXC Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas ASXC's P/E ratio is -1.12. In terms of profitability, AXGN's ROE is -0.18%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, AXGN is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for AXGN.Check ASXC's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
AXGN vs LUCD Comparison October 2026
AxoGen, Inc. (NASDAQ: AXGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2B. In comparison, LUCD has a market cap of 91.3M. Regarding current trading prices, AXGN is priced at $34.62 on the NASDAQ, while LUCD trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of 91.13, whereas LUCD's P/E ratio is -1.29. In terms of profitability, AXGN's ROE is -0.18%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, AXGN is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for AXGN.Check LUCD's competition here